Effect of oral hesperidin supplementation on glycemic and lipidemicin risk factors and inflammatory and oxidant markers in type 2 diabetes

Assessment of the effect of oral hesperidin supplement on glycemic and lipidemic risk factors, visceral adiposity index, serum levels of oxidant, inflammatory and oxidative DNA damage markers in type 2 diabetic patients: A randomized, double-blind, placebo-controlled clinical trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015081810181N6

Enrollment

Registered

2015-10-02

Start date

2015-09-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes. Diabetes mellitus

Interventions

Intervention 1: oral Hesperidin, 600 mg , one capsule per day for 6 weeks. Intervention 2: oral placebo, 600 mg , one capsule per day for 6 weeks.

Treatment - Other

oral Hesperidin, 600 mg , one capsule per day for 6 weeks

oral placebo, 600 mg , one capsule per day for 6 weeks

Eligibility

Sex/Gender

All

Age

25 Years to 60 Years

Inclusion criteria

Inclusion criteria: inclusion criteria: having type 2 diabetes for at least 3 years, oral hypoglycemic medications consumption and having informed written consent exclusion criteria: any change in type or dose of drug during the last 3 months, BMI ranges above 30, having history of other endocrine disorders, heart, hepatic and kidney diseases,using steroid drugs or hormones, having vitamin or mineral supplementation during previous 3 month

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Viseral Adiposity Index. Timepoint: baseline, 6 weeks after intervention period. Method of measurement: calculating by formula.;Fasting Glucose. Timepoint: baseline, 6 weeks after intervention period. Method of measurement: Fasting serum Glucose concentration in mg/dl by kit.;Insulin. Timepoint: baseline, 6 weeks after intervention period. Method of measurement: Fasting serum Insulin concentration in µU/ml by kit.;Serum Fructosamine. Timepoint: baseline, 6 weeks after intervention period. Method of measurement: Fasting serum Fructosamine concentration in µmol/L by kit.;Serum cholestrol. Timepoint: baseline, 6 weeks after intervention period. Method of measurement: Fasting Serum cholestrol concentration in mg/dl by kit.;HDL Cholestrol. Timepoint: baseline, 6 weeks after intervention period. Method of measurement: Fasting Serum HDL Cholestrol concentration in mg/dl by kit.;LDL Cholestrol. Timepoint: baseline, 6 weeks after intervention period. Method of measurement: Fasting Serum HDL Cholestrol concentration in mg/dl, calculating by Friedewald formula.;Serum Teriglycerid. Timepoint: Baseline, 6 weeks after intervention period. Method of measurement: Fasting serum Teriglycerid concentration in mg/dl by kit.;TNF-a. Timepoint: baseline, 6 weeks after intervention period. Method of measurement: Fasting serum TNF-a concentration in ng/L by kit.;IL-6. Timepoint: baseline, 6 weeks after intervention period. Method of measurement: Fasting serum IL-6 concentration in ng/L by kit.;Hs- CRP. Timepoint: baseline, 6 weeks after intervention period. Method of measurement: serum hs- CRP concentration in mg/L by kit.;Total Antioxidant Capacity. Timepoint: baseline, 6 weeks after intervention period. Method of measurement: Fasting serum Total Antioxidant Capacity in U/ml by kit.;Serum malondialdehyde. Timepoint: baseline, 6 weeks after intervention period. Method of measurement: Fasting serum malondialdehyde concentration in µmol/ml by kit.;8OHdG. Timepoint: baseline, 6 weeks after in	—

Measure

Time frame

Viseral Adiposity Index. Timepoint: baseline, 6 weeks after intervention period. Method of measurement: calculating by formula.;Fasting Glucose. Timepoint: baseline, 6 weeks after intervention period. Method of measurement: Fasting serum Glucose concentration in mg/dl by kit.;Insulin. Timepoint: baseline, 6 weeks after intervention period. Method of measurement: Fasting serum Insulin concentration in µU/ml by kit.;Serum Fructosamine. Timepoint: baseline, 6 weeks after intervention period. Method of measurement: Fasting serum Fructosamine concentration in µmol/L by kit.;Serum cholestrol. Timepoint: baseline, 6 weeks after intervention period. Method of measurement: Fasting Serum cholestrol concentration in mg/dl by kit.;HDL Cholestrol. Timepoint: baseline, 6 weeks after intervention period. Method of measurement: Fasting Serum HDL Cholestrol concentration in mg/dl by kit.;LDL Cholestrol. Timepoint: baseline, 6 weeks after intervention period. Method of measurement: Fasting Serum HDL Cholestrol concentration in mg/dl, calculating by Friedewald formula.;Serum Teriglycerid. Timepoint: Baseline, 6 weeks after intervention period. Method of measurement: Fasting serum Teriglycerid concentration in mg/dl by kit.;TNF-a. Timepoint: baseline, 6 weeks after intervention period. Method of measurement: Fasting serum TNF-a concentration in ng/L by kit.;IL-6. Timepoint: baseline, 6 weeks after intervention period. Method of measurement: Fasting serum IL-6 concentration in ng/L by kit.;Hs- CRP. Timepoint: baseline, 6 weeks after intervention period. Method of measurement: serum hs- CRP concentration in mg/L by kit.;Total Antioxidant Capacity. Timepoint: baseline, 6 weeks after intervention period. Method of measurement: Fasting serum Total Antioxidant Capacity in U/ml by kit.;Serum malondialdehyde. Timepoint: baseline, 6 weeks after intervention period. Method of measurement: Fasting serum malondialdehyde concentration in µmol/ml by kit.;8OHdG. Timepoint: baseline, 6 weeks after in

—

Secondary

Measure	Time frame
Body Mass Index. Timepoint: baseline, 6 weeks after intervention period. Method of measurement: body weight / hight square (kg/m2).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFatemeh Haidari

Dept. of Nutrition, School of Paramedical

haidari58@gmail.com+98 61 3373 8330

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026